Get to know our clinical trials

Trial of ravulizumab in adult and adolescent participants with thrombotic microangiopathy (TMA) after hematopoietic stem cell transplantation (HSCT).

THE PURPOSE OF THIS STUDY IS TO TEST WHETHER THE STUDY DRUG, RAVULIZUMAB, IS SAFE AND WHETHER IT CAN HELP PEOPLE WITH HSCT-MAT. THE CLINICAL TRIAL WILL INCLUDE ADULTS AND ADOLESCENTS.

Imagen del Dr. Jose Rifón Roca, especialista de Hematología de la Clínica Universidad de Navarra. El Dr. Rifón se dedica preferencialmente a la oncohematología.
Dr. José Rifón Curriculum
Specialist Hematology and Hemotherapy Department
Navarre headquarters
Madrid headquarters
Cancer Center
Hematologic Cancer Area
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE III, OPEN-LABEL, RANDOMIZED, MULTICENTER, MULTICENTER STUDY OF RAVULIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH THROMBOTIC MICROANGIOPATHY (TMA) AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT). IMMUNOTHERAPY
  • Code EudraCT: 2020-000144-61
  • Protocol number: ALXN1210-TMA-313
  • Promoter: Alexion Pharmaceuticals, Inc.

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION